Results 131 to 140 of about 4,984,958 (402)

Escape from TGF‐β‐induced senescence promotes aggressive hallmarks in epithelial hepatocellular carcinoma cells

open access: yesMolecular Oncology, EarlyView.
Chronic TGF‐β exposure drives epithelial HCC cells from a senescent state to a TGF‐β resistant mesenchymal phenotype. This transition is characterized by the loss of Smad3‐mediated signaling, escape from senescence, enhanced invasiveness and metastatic potential, and upregulation of key resistance modulators such as MARK1 and GRM8, ultimately promoting
Minenur Kalyoncu   +11 more
wiley   +1 more source

The making of bispecific antibodies

open access: yesmAbs, 2017
During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The ‘zoo’ of bispecific antibodies is populated by many different species, comprising around 100 different formats, including small ...
U. Brinkmann, R. Kontermann
semanticscholar   +1 more source

ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

open access: yesMolecular Oncology, EarlyView.
We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau   +11 more
wiley   +1 more source

Cellular delivery of antibodies: effective targeted subcellular imaging and new therapeutic tool [PDF]

open access: yes, 2010
It is already more than a century since the pioneering work of the Nobel Laureate Ehrlich gave birth to the side chain theory1, which helped to define antibodies and their ability to target specific biological sites.
Andrew L. Lewis   +6 more
core   +1 more source

Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial [PDF]

open access: yes, 2004
Background: Patients with irritable bowel syndrome (IBS) often feel they have some form of dietary intolerance and frequently try exclusion diets. Tests attempting to predict food sensitivity in IBS have been disappointing but none has utilised IgG ...
Atkinson, W.   +3 more
core   +3 more sources

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

open access: yesNature, 2018
Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in which a combination of 3BNC117 and 10-1074, two potent monoclonal ...
Pilar Mendoza   +35 more
semanticscholar   +1 more source

Multi‐omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine

open access: yesMolecular Oncology, EarlyView.
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti   +10 more
wiley   +1 more source

Publisher Correction: An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence

open access: yesNature Communications, 2019
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Chang-Han Lee   +18 more
doaj   +1 more source

Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. [PDF]

open access: yes, 2019
Broadly neutralizing monoclonal antibodies protect against infection with HIV-1 in animal models, suggesting that a vaccine that elicits these antibodies would be protective in humans.
Abernathy, Morgan E   +31 more
core  

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

open access: yesNature, 2021
E. Cameroni   +55 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy